Evidence map›Paper›PMID 32080098›Full record

Observational studyMedicine2020

Initial high-dose corticosteroids and renal impairment are risk factors for early severe infections in elderly patients with antineutrophil cytoplasmic autoantibody-associated vasculitis: A retrospective observational study.

Daisuke Waki, Keisuke Nishimura, Hironobu Tokumasu, Keiichiro Kadoba, Hiroki Mukoyama, Rintaro Saito, Hiroyuki Murabe, Toshihiko Yokota

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Review
  4. Understanding the burden of ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026
    Review
  5. Review
  6. Oxaliplatin-induced diffuse alveolar hemorrhage: A case report.World journal of clinical oncology · 2025
    Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Glucocorticoid-free treatment of severe ANCA-associated vasculitis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2021
    Article
  17. Observational
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Daisuke WakiDepartment of Endocrinology and Rheumatology.
Keisuke NishimuraDepartment of Endocrinology and Rheumatology.
Hironobu TokumasuDepartment of Management, Clinical Research Center, Kurashiki Central Hospital, Okayama, Japan.
Keiichiro KadobaDepartment of Endocrinology and Rheumatology.
Hiroki MukoyamaDepartment of Endocrinology and Rheumatology.
Rintaro SaitoDepartment of Endocrinology and Rheumatology.
Hiroyuki MurabeDepartment of Endocrinology and Rheumatology.
Toshihiko YokotaDepartment of Endocrinology and Rheumatology.
Kurashiki Central Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent large observational studies of antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) show that severe infection is a major cause of death and that the majority of infections occur during the early phase of initiating remission-induction therapy. Many risk factors for severe infection have been suggested, but these have been inconsistent. Nevertheless, infectious risk factors in elderly patients with AAV have not been adequately investigated in previous studies.In this retrospective observational study, we examined potential predictors of severe infection within 90 days (early severe infections) after remission-induction therapy in patients with AAV aged 65 years or older. We included 167 consecutive elderly patients with AAV admitted to our hospital. Data from medical history and remission-induction therapy were analyzed for predictive risk factors associated with early severe infections. The relationship between initial doses of corticosteroids and cumulative incidence of severe infections was also analyzed. A multivariate analysis of risk factors for early severe infections was performed using logistic regression analysis. The Kaplan-Meier method was used to estimate the overall survival, and the log-rank test was used to evaluate the differences between patients with and without early severe infections. Gray method was used to compare the cumulative incidence of severe infections in patients who did and did not receive initial high-dose corticosteroids.Logistic regression analysis showed that initial high-dose corticosteroid administration (prednisolone ≥0.8 mg/kg/d) (odds ratio [OR] 3.86, P = .030) and serum creatinine levels at diagnosis ≥1.5 mg/dL (OR 5.13, P = .003) were independent predictors of early severe infection although administration of cyclophosphamide or rituximab was not. The cumulative incidence of severe infections was also significantly higher in patients who received initial high-dose corticosteroids (P = .042), and patients with early severe infections exhibited a high mortality rate within 6 months (P < .001).Our findings suggest that initial high-dose corticosteroids and renal impairment at diagnosis are associated with a higher risk of early severe infections and early death in elderly patients with AAV.

Indexed as

Adrenal Cortex HormonesAgedAged, 80 and overAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisBacterial InfectionsCreatinineDose-Response Relationship, DrugFemaleHumansImmunosuppressive AgentsKaplan-Meier EstimateLogistic ModelsMaleRenal InsufficiencyRetrospective StudiesRisk FactorsAdrenal Cortex HormonesCreatinineImmunosuppressive Agents

Identifiers

PMID32080098
PMCPMC7034627
OpenAlexW3006825941

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.